" class="no-js "lang="en-US"> Caris’ Precision Oncology Alliance Welcomes The Georgia Cancer Center at Augusta University - Medtech Alert
Thursday, June 20, 2024

Caris’ Precision Oncology Alliance Welcomes The Georgia Cancer Center at Augusta University

Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the Georgia Cancer Center at Augusta University has joined Caris’ Precision Oncology Alliance (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

The Georgia Cancer Center has a long history of bringing clinical trials, including therapies developed in its own labs, to both adults and children with all types of cancer. Its relationship with the National Cancer Institute (NCI) community oncology research programs began in 1994 with a predecessor, the minority-based community clinical oncology program, or MBCCOP. Today, the Georgia Cancer Center continues to lead the state’s only minority-based research program through the NCI’S NCORP.

“We are excited to collaborate with other leading institutions focused on research and innovation through Caris’ Precision Oncology Alliance,” said Jorge E. Cortes, M.D., Director, Georgia Cancer Center. “We are convinced that through clinical and translational research we do not only provide the best patient care, but lead into the necessary improvements in diagnosis, prevention and treatment of cancer, now and in the future.”

The Georgia Cancer Center is on a path to achieve National Cancer Institute designation through NCI’s Cancer Center Support Grant program — looking to become only the second institution in the state to do so. By definition, an NCI-designated cancer center is a leader in nationally recognized cancer research, which includes clinical trials.

“The Georgia Cancer Center’s multidisciplinary approach to cancer care allows their physicians and researchers to focus on fostering innovation to improve patient outcomes,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “The POA is excited to work with partners like the Georgia Cancer Center who support eliminating the threat of cancer by offering access to high-quality, research-based cancer care to everyone in their community. The clinical research talent that the Georgia Cancer Center has compliments the POA’s strategic vision and mission statements, and is destined to enhance ongoing research capabilities.”

“The Georgia Cancer Center at Augusta University offers the most advanced cancer care in the region,” said Brian J. Brille, Vice Chairman of Caris Life Sciences. “Their team of top oncology physicians and researchers are able to support patients and their families with the latest cutting-edge treatment options in precision medicine, and the POA welcomes their expertise in the field.”

Serving a dozen Georgia counties, the Georgia Cancer Center offers comprehensive care for children and adults using a patients-first model, which emphasizes the best treatments available along with a wide range of supportive services, including integrative medicine. It also features multidisciplinary tumor boards, dedicated clinical trials research units, nurse navigators, on-site fusion, on-campus radiation oncology and blood and marrow transplant services, as well as surgical and medical oncology with the region’s largest team of cancer specialists.

The Caris Precision Oncology Alliance includes 55 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1,000,000 data points per patient.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more